Comparing Oral Trimethoprim-Sulfamethoxazole and Clindamycin Treatments for Children Aged 2 to 18 With Invasive MRSA Infections

What this Trial Is About

Researchers are evaluating the use of trimethoprim-sulfamethoxazole TMP-SMX compared to clindamycin for treating invasive infections caused by methicillin-resistant Staphylococcus aureus MRSA in children. The study aims to find out if TMP-SMX is effective and safe for children with these infections. It will compare how well TMP-SMX works against clindamycin, a commonly prescribed antibiotic, in treating these serious infections. Participants will receive either TMP-SMX or clindamycin as treatment. TMP-SMX dosing varies depending on the infection type, for osteoarticular infections it is given every 8 hours, and for head and neck infections, every 12 hours, with the treatment duration decided by the treating provider. Clindamycin is given every 8 hours with a dose based on body weight, and treatment length is also up to the providers discretion. During the study, participants will follow their healthcare providers guidance and keep a diary to track symptoms and any side effects. Researchers will monitor treatment success six weeks and six months after hospitalization and track any antibiotic-related side effects. The total study duration spans up to six months post-hospitalization, with follow-up visits as needed based on the treating providers decisions.

Trimethoprim-sulfamethoxazole vs. Clindamycin for the Treatment of Children With Invasive MRSA Infections